Samia Rekik1, Erwan Guyot2, Mohannad Bhais1, Yves Ajavon3, Véronique Grando1, Valérie Bourcier1, Gisèle Nkontchou1, Pierre Nahon4, Nicolas Sellier5, Olivier Seror6, Nathalie Ganne-Carrie4, Jean-Charles Nault7. 1. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Liver Unit, Bondy, France. 2. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Biochemistry Department, Bondy, France. 3. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Radiology Department, Bondy, France. 4. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Liver Unit, Bondy, France; Inserm, UMR-1162, Functional Genomic of Solid Tumors, Team "Ligue Contre le Cancer", Paris, France; Paris Descartes University, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France; Paris 13 University, Sorbonne Paris Cité, UFR SMBH, Bobigny, France; Paris Diderot University, Paris, France. 5. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Radiology Department, Bondy, France; Paris 13 University, Sorbonne Paris Cité, UFR SMBH, Bobigny, France. 6. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Radiology Department, Bondy, France; Inserm, UMR-1162, Functional Genomic of Solid Tumors, Team "Ligue Contre le Cancer", Paris, France; Paris Descartes University, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France; Paris 13 University, Sorbonne Paris Cité, UFR SMBH, Bobigny, France; Paris Diderot University, Paris, France. 7. APHP, Hôpitaux universitaires Paris - Seine Saint-Denis, Jean Verdier, Liver Unit, Bondy, France; Inserm, UMR-1162, Functional Genomic of Solid Tumors, Team "Ligue Contre le Cancer", Paris, France; Paris Descartes University, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France; Paris 13 University, Sorbonne Paris Cité, UFR SMBH, Bobigny, France; Paris Diderot University, Paris, France. Electronic address: naultjc@gmail.com.
Abstract
BACKGROUND: Prognostic biomarkers are needed in a heterogeneous population of patients with intermediate hepatocellular carcinoma (HCC) treated by transarterial (chemo)embolization. We aimed to validate the prognostic value of serum CRP levels and the STATE score, combining CRP, albumin and tumor burden. METHODS: All cirrhotic patients with HCC treated by a first transarterial (chemo)embolization (2007-2013) in our institution were included. Overall survival was assessed using the Kaplan-Meier method, log rank, univariate and multivariate Cox analyses. RESULTS: Among 157 patients included, 87% were men, 86% had Child Pugh A. Etiologies of liver disease included alcohol (57%), hepatitis C (32%), hepatitis B (11%) and/or metabolic syndrome (32%); 89% of patients were classified BCLC B. 33% of the patients had a CRP >1mg/dl and 33% a STATE score conferring poor prognosis (<18). Patients with CRP <1mg/dl had better overall survival than patients with CRP >1mg/dl (20 vs. 8 months, P=0.00186). Median overall survival was 6.73 months for patients with a STATE score <18 vs. 22.23 months for patients with STATE-score ≥18 (P=0.0002). In multivariate analysis, a STATE score <18 was independently associated with increased mortality (HR: 2.06 (CI95%: 1.28-3.34), P=0.0031). CONCLUSION: In cirrhotic patients with HCC who underwent transarterial treatment, serum CRP level and STATE score at baseline can predict overall survival.
BACKGROUND: Prognostic biomarkers are needed in a heterogeneous population of patients with intermediate hepatocellular carcinoma (HCC) treated by transarterial (chemo)embolization. We aimed to validate the prognostic value of serum CRP levels and the STATE score, combining CRP, albumin and tumor burden. METHODS: All cirrhotic patients with HCC treated by a first transarterial (chemo)embolization (2007-2013) in our institution were included. Overall survival was assessed using the Kaplan-Meier method, log rank, univariate and multivariate Cox analyses. RESULTS: Among 157 patients included, 87% were men, 86% had Child Pugh A. Etiologies of liver disease included alcohol (57%), hepatitis C (32%), hepatitis B (11%) and/or metabolic syndrome (32%); 89% of patients were classified BCLC B. 33% of the patients had a CRP >1mg/dl and 33% a STATE score conferring poor prognosis (<18). Patients with CRP <1mg/dl had better overall survival than patients with CRP >1mg/dl (20 vs. 8 months, P=0.00186). Median overall survival was 6.73 months for patients with a STATE score <18 vs. 22.23 months for patients with STATE-score ≥18 (P=0.0002). In multivariate analysis, a STATE score <18 was independently associated with increased mortality (HR: 2.06 (CI95%: 1.28-3.34), P=0.0031). CONCLUSION: In cirrhotic patients with HCC who underwent transarterial treatment, serum CRP level and STATE score at baseline can predict overall survival.